BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 30998207)

  • 1. Erythema multiforme-like rash upon anti-melanoma therapy with BRAF and MEK inhibitors.
    Grän F; Goebeler M; Gesierich A
    Eur J Dermatol; 2019 Feb; 29(1):107-108. PubMed ID: 30998207
    [No Abstract]   [Full Text] [Related]  

  • 2. Possible immune adverse events as predictors of durable response to BRAF inhibitors in patients with BRAF V600-mutant metastatic melanoma.
    Ben-Betzalel G; Baruch EN; Boursi B; Steinberg-Silman Y; Asher N; Shapira-Frommer R; Schachter J; Markel G
    Eur J Cancer; 2018 Sep; 101():229-235. PubMed ID: 30096703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization and Outcomes of Disease Progression in 52 Patients Treated with BRAF-V600 + MEK Inhibitors for Advanced Melanoma.
    Lucas P; Boulinguez S; Sibaud V; Mourey L; Lamant L; Paul C; Meyer N
    Dermatology; 2018; 234(3-4):92-98. PubMed ID: 30110681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.
    Ribas A; Gonzalez R; Pavlick A; Hamid O; Gajewski TF; Daud A; Flaherty L; Logan T; Chmielowski B; Lewis K; Kee D; Boasberg P; Yin M; Chan I; Musib L; Choong N; Puzanov I; McArthur GA
    Lancet Oncol; 2014 Aug; 15(9):954-65. PubMed ID: 25037139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.
    Larkin J; Ascierto PA; Dréno B; Atkinson V; Liszkay G; Maio M; Mandalà M; Demidov L; Stroyakovskiy D; Thomas L; de la Cruz-Merino L; Dutriaux C; Garbe C; Sovak MA; Chang I; Choong N; Hack SP; McArthur GA; Ribas A
    N Engl J Med; 2014 Nov; 371(20):1867-76. PubMed ID: 25265494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients.
    Sullivan RJ; Hamid O; Gonzalez R; Infante JR; Patel MR; Hodi FS; Lewis KD; Tawbi HA; Hernandez G; Wongchenko MJ; Chang Y; Roberts L; Ballinger M; Yan Y; Cha E; Hwu P
    Nat Med; 2019 Jun; 25(6):929-935. PubMed ID: 31171876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The safety and efficacy of cobimetinib for the treatment of BRAF V600E or V600K melanoma.
    Amaral T; Nouri N; Garbe C
    Expert Rev Anticancer Ther; 2016 Jul; 16(7):705-15. PubMed ID: 27219630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study.
    Dréno B; Ribas A; Larkin J; Ascierto PA; Hauschild A; Thomas L; Grob JJ; Koralek DO; Rooney I; Hsu JJ; McKenna EF; McArthur GA
    Ann Oncol; 2017 May; 28(5):1137-1144. PubMed ID: 28444112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Demyelinating polyradiculoneuropathy under combined BRAF/MEK inhibitors.
    Devic P; Amini-Adle M; Camdessanché JP; Dalle S
    Eur J Cancer; 2017 Jun; 78():103-104. PubMed ID: 28432982
    [No Abstract]   [Full Text] [Related]  

  • 10. Atypical systemic sarcoid-like granulomatosis in two patients treated with BRAF and MEK inhibitors.
    Assan F; Schlemmer F; Assie JB; Mahevas M; Sustronck P; Ortonne N; Velter C; Fardet L; Zehou O
    Eur J Dermatol; 2019 Oct; 29(5):556-557. PubMed ID: 31649010
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma.
    Sanlorenzo M; Choudhry A; Vujic I; Posch C; Chong K; Johnston K; Meier M; Osella-Abate S; Quaglino P; Daud A; Algazi A; Rappersberger K; Ortiz-Urda S
    J Am Acad Dermatol; 2014 Dec; 71(6):1102-1109.e1. PubMed ID: 25440439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
    Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
    Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management.
    Gogas HJ; Flaherty KT; Dummer R; Ascierto PA; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Sileni VC; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Gollerkeri A; Pickard MD; Robert C
    Eur J Cancer; 2019 Sep; 119():97-106. PubMed ID: 31437754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series.
    Naqash AR; File DM; Ziemer CM; Whang YE; Landman P; Googe PB; Collichio FA
    J Immunother Cancer; 2019 Jan; 7(1):4. PubMed ID: 30621779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.
    Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
    Lancet Oncol; 2018 Oct; 19(10):1315-1327. PubMed ID: 30219628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic inflammatory reaction syndrome during combined kinase inhibitor therapy following anti-PD-1 therapy for melanoma.
    Urosevic-Maiwald M; Mangana J; Dummer R
    Ann Oncol; 2017 Jul; 28(7):1673-1675. PubMed ID: 28459947
    [No Abstract]   [Full Text] [Related]  

  • 17. Skin cancer: BRAF and MEK inhibitors-good news comes in twos!
    Killock D
    Nat Rev Clin Oncol; 2014 Dec; 11(12):683. PubMed ID: 25331181
    [No Abstract]   [Full Text] [Related]  

  • 18. Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma.
    Daud A; Tsai K
    Oncologist; 2017 Jul; 22(7):823-833. PubMed ID: 28526719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cobimetinib and vemurafenib for the treatment of melanoma.
    Boespflug A; Thomas L
    Expert Opin Pharmacother; 2016; 17(7):1005-11. PubMed ID: 26999478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials.
    Hauschild A; Larkin J; Ribas A; Dréno B; Flaherty KT; Ascierto PA; Lewis KD; McKenna E; Zhu Q; Mun Y; McArthur GA
    JAMA Oncol; 2018 Oct; 4(10):1382-1388. PubMed ID: 30073321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.